08:00 , Dec 21, 2015 |  BC Week In Review  |  Clinical News

Acetylon preclinical data

In rats and monkeys, once-daily oral ACY-957 increased hemoglobin subunit epsilon 1 ( HBE1 ; HBE ) and hemoglobin subunit gamma (HBG) globin mRNA, respectively, in peripheral blood. ACY-957 is a selective histone deacetylase 1...
08:00 , Dec 24, 2007 |  BC Week In Review  |  Clinical News

Tyzeka telbivudine: Additional Phase III data

Previously reported 1-year data from the Phase III GLOBE study were published in The New England Journal of Medicine and showed that 600 mg/day of oral telbivudine was non-inferior to 100 mg/day of lamivudine. In...
07:00 , Jul 25, 2005 |  BC Week In Review  |  Clinical News

Tenofovir disoproxil fumarate: Phase III started

GILD began the double-blind, international, Phase III Study 102 trial in about 300 patients with HBeAg-negative/anti-HBe positive chronic HBV. In the trial 200 patients will receive 300 mg once-daily tenofovir and 100 patients will receive...
08:00 , Mar 18, 2002 |  BC Week In Review  |  Clinical News

Zadaxin thymosin alpha 1 plus interferon: Phase II results; Phase III

Twelve-month follow-up data from a Turkish Phase II trial in 31 patients with chronic HBV showed that 71% (15/21) of patients treated with Zadaxin plus alpha interferon from Schering-Plough Corp. (SGP, Kenilworth, N.J.) maintained normal...
07:00 , Jun 1, 1998 |  BC Week In Review  |  Clinical News

Zadaxin thymosin alpha 1: Phase III data; marketed in Asia

SCLN published in Hepatology results from a single site involving 98 patients out of a total of 158 patients enrolled in SCLN's Phase III trial in Taiwan (see BioCentury, Aug. 5, 1996). Among patients given...
07:00 , Apr 13, 1998 |  BC Week In Review  |  Clinical News

Preveon adefovir dipivoxil nucleotide analog reverse transcriptase inhibitor: Phase II

Results from 29 patients in the first dose cohort in a double-blind placebo-controlled Phase II study in patients infected with hepatitis B virus (HBV) demonstrated that adefovir treatment could reduce levels of HBV to below...
08:00 , Mar 30, 1998 |  BC Week In Review  |  Clinical News

Lamivudine 3TC: Phase III; awaiting marketing approval

BCHE reported data from trials comparing the combination of lamivudine with Intron A versus either alone. A total of 226 patients were randomized to received 100 mg lamivudine once daily for 52 weeks, 10 MU...
08:00 , Jan 27, 1997 |  BC Week In Review  |  Clinical News

Hepagene hepatitis B vaccine containing all HBV surface antigens data

MDV announced results of a U.K. trial demonstrating Hepagene's effectiveness in 925 patients who were not seroprotected after at least 3 doses of Engerix-B, a vaccine produced by SmithKline Beecham (Philadelphia, Penn.). Patients received either...
08:00 , Nov 18, 1996 |  BC Week In Review  |  Clinical News

Lamivudine data

Preliminary data from a Phase II study in 24 patients, of whom 23 were evaluable, show that persistent suppression of chronic hepatitis B infection is possible with extended use of lamivudine. As reported at the...
07:00 , Sep 23, 1996 |  BC Week In Review  |  Clinical News

GS 840 nucleotide analog data

GILD reported results of a Phase I/II trial of GS 840 in 20 patients with hepatitis B, showing reduced viral load that reverted toward baseline after the end of the four-week study. As reported at...